About: Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials
Creator	Al-Horani, Rami Aliter, Kholoud Kar, Srabani
Source	Medline; PMC
abstract	The ongoing pandemic of coronavirus disease-2019 (COVID-19) is being caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The disease continues to present significant challenges to the health care systems around the world. This is primarily because of the lack of vaccines to protect against the infection and the lack of highly effective therapeutics to prevent and/or treat the illness. Nevertheless, researchers have swiftly responded to the pandemic by advancing old and new potential therapeutics into clinical trials. In this review, we summarize potential anti-COVID-19 therapeutics that block the early stage of the viral life cycle. The review presents the structures, mechanisms, and reported results of clinical trials of potential therapeutics that have been listed in clinicaltrials.gov. Given the fact that some of these therapeutics are multi-acting molecules, other relevant mechanisms will also be described. The reviewed therapeutics include small molecules and macromolecules of sulfated polysaccharides, polypeptides, and monoclonal antibodies. The potential therapeutics target viral and/or host proteins or processes that facilitate the early stage of the viral infection. Frequent targets are the viral spike protein, the host angiotensin converting enzyme 2, the host transmembrane protease serine 2, and clathrin-mediated endocytosis process. Overall, the review aims at presenting update-to-date details, so as to enhance awareness of potential therapeutics, and thus, to catalyze their appropriate use in combating the pandemic.
has issue date	2020-07-23(xsd:dateTime)
bibo:doi	10.3390/ijms21155224
bibo:pmid	32718020
has license	cc-by
sha1sum (hex)	65987d1145dd499f005373a01f3e3df3fecde0be
schema:url	https://doi.org/10.3390/ijms21155224
resource representing a document's title	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials
has PubMed Central identifier	PMC7432953
has PubMed identifier	32718020
schema:publication	Int J Mol Sci
resource representing a document's body	covid:65987d1145dd499f005373a01f3e3df3fecde0be#body_text
is schema:about of	named entity 'transmembrane' named entity 'therapeutics' named entity 'serine' named entity 'spike' named entity 'Given' named entity 'host' named entity 'protease' named entity 'Clinical Trials' named entity 'REVIEWED' named entity 'RESEARCHERS' named entity 'THERAPEUTICS' named entity 'CHALLENGES' named entity 'FREQUENT' named entity 'ENHANCE' named entity 'mechanisms' named entity 'sulfated' named entity 'responded' named entity 'highly' named entity 'clinical trials' named entity 'protein' named entity 'small molecules' named entity 'mechanisms' named entity 'therapeutics' named entity 'pulmonary diseases' named entity 'quinoline' named entity 'furin' named entity 'nucleotides' named entity 'serine protease inhibitors' named entity 'lopinavir/ritonavir' named entity 'immunomodulatory' named entity 'COVID-19' named entity 'convalescent plasma' named entity 'COVID-19' named entity 'mechanical ventilation' named entity 'Metabolism' named entity 'hydroxychloroquine' named entity 'health care professionals' named entity 'hypertension' named entity 'asymptomatic' named entity 'COVID-19' named entity 'control patients' named entity 'trypsin' named entity 'U.S.' named entity 'hematopoietic cells' named entity 'mast cells' named entity 'Wuhan' named entity 'SARS-CoV' named entity 'host cells' named entity 'retrospective cohort study' named entity 'ARBs' named entity 'mefloquine' named entity 'COVID-19 pandemic' named entity 'umifenovir' named entity 'antipsychotic' named entity 'cytokines' named entity 'ARBs' named entity 'trypsin' named entity 'viral replication' named entity 'protein' named entity 'genetic material' named entity 'anti-inflammatory' named entity 'proximal tubular' named entity 'U.S. FDA' named entity 'nucleocapsid' named entity 'SARS-CoV-2' named entity 'chloroquine' named entity 'SARS-CoV' named entity 'mouse models' named entity 'baricitinib' named entity 'statins' named entity 'parasite' named entity 'gastrointestinal' named entity 'viral entry' named entity 'COVID' named entity 'critically ill patients' named entity 'COVID-19' named entity 'elimination half-life' named entity 'ICU' named entity 'Figure 8'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software